Market Place
Sourcing Support
Atea Pharma to Present & Update at Evercore HealthCONx Conference
26 Nov 2024 //
GLOBENEWSWIRE
Atea Supports Bemnifosbuvir-Ruzasvir Combo for Hepatitis C at AASLD
15 Nov 2024 //
GLOBENEWSWIRE
Atea Pharma Reports Q3 2024 Financial Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Atea Pharma to Host Q3 2024 Financial Results Call on Nov 7, 2024
31 Oct 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present Hepatitis C Data at AASLD
30 Oct 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Updates Global Phase 3 SUNRISE-3 Trial Of Bemnifosbuvir
13 Sep 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Publishes Data On Bemnifosbuvir`s Activation
28 Aug 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Reports Q2 2024 Results And Business Update
07 Aug 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals To Host Q2 2024 Results Call On August 7
31 Jul 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
29 May 2024 //
GLOBENEWSWIRE
Atea Shows Bemnifosbuvir-Ruzasvir HCV Combo Potential At EASL
22 May 2024 //
GLOBENEWSWIRE
Atea Pharma Reports Q1 2024 Results, Business Update
14 May 2024 //
GLOBENEWSWIRE
Atea To Host Q1 2024 Results Call On May 14
07 May 2024 //
GLOBENEWSWIRE
Atea`s Bemnifosbuvir Safety Data at ESCMID Global 2024
29 Apr 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Completes Patient Enrollment for Phase 3 SUNRISE-3 Trial
27 Mar 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
28 Feb 2024 //
GLOBENEWSWIRE
Atea to Host Fourth Quarter and Full Year 2023 Financial Results
21 Feb 2024 //
GLOBENEWSWIRE
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for HCV
08 Jan 2024 //
GLOBENEWSWIRE
Atea Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
GLOBENEWSWIRE
Atea Pharma Presents Promising Bemnifosbuvir and Ruzasvir Combination Data
13 Nov 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals Announces Participation at Upcoming Investor Conferences
08 Nov 2023 //
GLOBENEWSWIRE
Atea Reports Third Quarter 2023 Financial Results and Provides Business Update
08 Nov 2023 //
GLOBENEWSWIRE
Atea to Present Bemnifosbuvir and Ruzasvir Data for Hepatitis C Virus
02 Nov 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Host Third Quarter 2023 Financial Results
01 Nov 2023 //
GLOBENEWSWIRE
Atea to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
06 Sep 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results
08 Aug 2023 //
GLOBENEWSWIRE
Atea to Host Q2 2023 Financial Results Conference Call on August 8, 2023
01 Aug 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Study fo
15 Jun 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present at the Jefferies Healthcare Conference
05 Jun 2023 //
GLOBENEWSWIRE
Atea rejects `undervalued` offer from Concentra
31 May 2023 //
FIERCE BIOTECH
Atea Pharma™ Board of Directors Unanimously Rejects Unsolicited Proposal
30 May 2023 //
GLOBENEWSWIRE
Atea Confirms Receipt of Proposal from Tang Partners Affiliate, Concentra
23 May 2023 //
GLOBENEWSWIRE
Atea confirms unsolicited cash proposal from Tang Capital’s Concentra
23 May 2023 //
ENDPTS
Atea Pharmaceuticals Reports 1Q 2023 FYR and Provides Business Update
08 May 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Host 1Q 2023 Financial Results
01 May 2023 //
GLOBENEWSWIRE
Atea Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir
25 Apr 2023 //
GLOBENEWSWIRE
Atea Announces Presentation of Bemnifosbuvir Data Showing Reduced Hospitalizations for COVID-19 Patients
12 Apr 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals announces results of bemnifosbuvir for Covid-19
15 Mar 2023 //
CLINICAL TRIALS ARENA
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19
08 Mar 2023 //
GLOBENEWSWIRE
Atea dumps dengue drug as forecast R&D timelines, costs spiral
01 Mar 2023 //
FIERCE BIOTECH
Atea Reports Fourth Quarter and Full Year 2022 Financial Results
28 Feb 2023 //
GLOBENEWSWIRE
CooperCompanies to Present at KeyBanc Life Sciences & MedTech Investor Forum
28 Feb 2023 //
GLOBENEWSWIRE
Atea Presents Favorable Drug Interaction Profile of Bemnifosbuvir in PI Studies
23 Feb 2023 //
GLOBENEWSWIRE
Atea Pharma to Report Fourth Quarter and Full Year 2022 Financial Results
21 Feb 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present Data on Bemnifosbuvir Drug Interaction Profile
15 Feb 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present at SVB Securities Global Biopharma Conference
07 Feb 2023 //
GLOBENEWSWIRE
Atea Pharmaceuticals Highlights Strategic Priorities for 2023
09 Jan 2023 //
GLOBENEWSWIRE
Atea Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
GLOBENEWSWIRE
Atea Announces First Patient Dosed in SUNRISE-3 Phase 3 Trial of Bemnifosbuvir
29 Nov 2022 //
GLOBENEWSWIRE
Atea Pharma to Present at the 5th Annual Evercore ISI HealthCONx Conference
22 Nov 2022 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Present at the Jefferies London Healthcare Conference
08 Nov 2022 //
GLOBENEWSWIRE
Atea Pharma Presents Favorable AT-752 Ph1 Data for Treatment of Dengue Fever
03 Nov 2022 //
GLOBENEWSWIRE
Atea Pharmaceuticals to Host Third Quarter 2022 Financial Results Conference
31 Oct 2022 //
GLOBENEWSWIRE
Atea Pharma Announces U.S. FDA Fast Track Designation Granted to AT-752
26 Sep 2022 //
GLOBENEWSWIRE
Atea to Advance Global Ph3 Registrational Study of Bemnifosbuvir in High-Risk
13 Sep 2022 //
GLOBENEWSWIRE
Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results
08 Aug 2022 //
GLOBENEWSWIRE
Atea Pharma to Host Q2 2022 Financial Results Conference Call
01 Aug 2022 //
GLOBENEWSWIRE
Atea Pharmaceuticals Participates in the William Blair Biotech Focus Conference
11 Jul 2022 //
GLOBENEWSWIRE
Atea Pharma shareholders have endured a 68% loss from investing in the stock
12 Jun 2022 //
YAHOO FINANCE
Atea Pharmaceuticals to Present at the 2022 Jefferies Healthcare Conference
01 Jun 2022 //
GLOBENEWSWIRE
